CJC-1295

Meet CJC-1295 – a synthetically engineered growth hormone-releasing hormone (GHRH) analog designed for duration and stability. Unlike native GHRH, it incorporates a Drug Affinity Complex (DAC) moiety that binds to albumin in the bloodstream, dramatically extending its half-life and creating a stable, sustained-release profile. For researchers investigating the systemic effects of prolonged growth hormone (GH) elevation – from body composition and metabolism to tissue repair and aging – CJC-1295 provides a unique and powerful pharmacological tool. 🔬 Imagine Replacing Pulsatile Signals with a Sustained Symphony. The body's natural GH release is pulsatile. CJC-1295 allows scientists to study the effects of a continuous, elevated GH/IGF-1 axis over days from a single administration. This enables groundbreaking research into chronic models of muscle growth, fat metabolism, bone density, and organ regeneration, offering insights that short-acting peptides cannot provide. Your work in endocrinology, gerontology, or metabolic disease gains a long-acting lever to precisely control a fundamental hormonal pathway.